CEPI awards $1.9M to Public Health Vaccines for Bundibugyo Ebola vaccine

What's the deal? The Coalition for Epidemic PreparednessDealroom has a profile for this one. Try Dealroom → Innovations (CEPI) has awarded a $1.9M grant to Public Health VaccinesDealroom has a profile for this one. Try Dealroom → (PHV), a Cambridge, Massachusetts-based company, to accelerate early-stage development of a vaccine targeting the Bundibugyo strain of Ebola. The funding will support production of "Master Viral Seed" stock — the foundational biological material needed to manufacture clinical-grade vaccine doses and move the candidate into human trials.

Why now? An ongoing Bundibugyo Ebola outbreak across the Democratic Republic of the Congo and neighbouring Uganda has recorded more than 560 confirmed cases and over 100 deaths. Health authorities have classified it as both a continental and global emergency.

There are currently no licensed vaccines — and no candidates in clinical development — specifically targeting this strain. Response efforts rely entirely on supportive care and containment, leaving a dangerous gap in global preparedness.

What could go wrong? PHV's candidate uses a recombinant vesicular stomatitis virus platform, the same viral vector technology behind a licensed vaccine for the Zaire strain of Ebola. While the platform has proven effective in previous outbreaks, adapting it to a different strain still carries scientific risk. Establishing seed stock is just the first step; clinical trials, regulatory approval, and scaled manufacturing all lie ahead.

"This epidemic is a stark reminder of how quickly deadly viruses can spread, especially in communities already under immense strain," said CEPI chief executive officer Richard Hatchett.

The signal: PHV remains an early-stage company, and CEPI — a government and non-profit backed funder — is effectively acting as a de-risking mechanism for a market that offers little commercial incentive. With no licensed Bundibugyo vaccine and no other candidates in clinical development, the portfolio bet CEPI is making across four experimental candidates underscores how dependent outbreak-driven vaccine development still is on public and philanthropic capital rather than private venture funding.

Read more: sciencenigeria.com